Pfizer Global Supply (PGS) produces over 23 billion doses of medicine annually across its network of 42 global sites. Expand Franklin – April 21, 2024: Pfizer site manufacturing heparin active pharmaceutical ingredient. Pfizer is a pharmaceutical biotechnology corporation. In 2016, the division embarked on a journey to optimise operations and support Pfizer’s overarching purpose of “breakthroughs that change patients’ lives.” The goal was to revolutionise the company’s manufacturing operations, leveraging data-driven insights to drive world-class performance. This initiative began with the leadership of the president of PGS. PGS’ network of facilities, stemming from more than 30 legacy pharmaceutical companies, relied on a wide range of systems and datasets, each with unique standards and protocols. As a result, obtaining actionable insights across the network was difficult, and modernising operations at the operational technologies (OT) level required a multi-year effort. A blank-slate approach to digital transformation In crafting its digital transformation strategy, PGS took a step back to thoroughly assess both its internal business challenges and the broader technological landscape within the pharmaceutical industry. Mike Tomasco, vice president of digital manufacturing at Pfizer, said: “We said, OK, if we could take a blank slate and start over, what would this look […]
Click here to view original web page at pharmaceuticalmanufacturer.media
